Pharma News

Biocon Limited an innovation-led global biopharmaceutical company announced the initiation of the clinical study of Itolizumab in patients with Ulcerative Colitis (UC) in India, in collaboration with Equillium Inc. This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naïve patients with moderate to severely active UC.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Heart failure management to go cheaper in the country with important drugs losing their patents in January 2023. The drug combination of sacubitril plus valsartan, which is an accepted combination for heart failure, is losing patent.

Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its Oncology Injectable Formulation Facility at Panelav.

US Food and Drug Administration (USFDA) for the inspection carried out by them at Alembic's Oncology Injectable Formulation Facility at Panelav during the period from 4th October, 2022 to 14th October, 2022.

Autoimmune diseases are thought to be the result of mistaken identity. Immune cells on patrol, armed and ready to defend the body against invading pathogens, mistake normal human cells for infected cells and turn their weapons on their own healthy tissues. In most cases, though, finding the source of the confusion the tiny fragment of normal human protein that looks dangerously similar to a protein from a pathogen  has been challenging for scientists.

Besides the skin, the digestive tract is the tissue that is most exposed to environmental influences such as bacteria and viruses. Therefore, cells that form these barriers to the interior of the body also have special defence mechanisms. A research team led by Professor Dr Thorsten Hoppe has now shown that RNA interference, or RNAi for short, which is known to be a viral defence mechanism, also prevents the overproduction of the body’s own proteins in intestinal cells.

A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine’s Abramson Cancer Center showed, suggesting the drug is a strong candidate for clinical trials. The study was published today in Cancer Discovery, a journal of the American Association for Cancer Research.

Preventing metastasis – the development of cancer cells beyond their original location – remains one of the major goals of current cancer research. Most malignant tumor cells metastasize by exploiting abnormal leakage from blood vessels. New work looks to further explore the role of how the alignment of endothelial cells, which line blood vessels, plays a role in the spread of cancer.

Pfizer Inc and BioNTech SE announced that the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age. With the high level of respiratory illnesses currently circulating among children under 5 years of age, updated COVID-19 vaccines may help prevent severe illness and hospitalization.